The new genetics of bipolar affective disorder

Clinical implications

J Raymond Depaulo, S. G. Simpson, S. Folstein, Marshal F. Folstein

Research output: Contribution to journalArticle

Abstract

Underrecognition and undertreatment of affective disorders (i.e., major depressive disorder and bipolar affective disorder) constitute a serious public health problem in this country. The recent availability of sufficient mapped restriction fragment length polymorphism (RFLP) probes to cover the human genome and of improved methods of genetic linkage analysis make the definition of the genetic basis of bipolar affective disorders (and recurrent depressions) feasible within the foreseeable future. However, the degree of genetic heterogeneity involved might make the use of tightly linked RFLPs for diagnostic testing, as has been done for Huntington's disease or cystic fibrosis, impractical. Assuming multiple disease loci, then widely applicable and useful 'molecular' diagnostic tests will await the cloning of the disease genes or identification of pathogenic gene products. In addition, the combination of genetic heterogeneity and a substantial degree of assortative mating (i.e., people with affective disorders marrying each other) in families with these disorders could make the search for linked loci a 'bottle-neck' in the path toward developing such diagnostic tests. Recently, three disease loci have been tentatively identified on chromosomes 6, 11, and X.

Original languageEnglish (US)
JournalClinical Chemistry
Volume35
Issue number7 SUPPL.
StatePublished - 1989

Fingerprint

Mood Disorders
Bipolar Disorder
Genetic Heterogeneity
Genes
Routine Diagnostic Tests
Restriction Fragment Length Polymorphisms
Chromosomes, Human, Pair 11
Chromosomes, Human, Pair 6
Genetic Linkage
Molecular Pathology
Cloning
Huntington Disease
Major Depressive Disorder
Bottles
Public health
Human Genome
Chromosomes
Medical problems
Polymorphism
Cystic Fibrosis

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The new genetics of bipolar affective disorder : Clinical implications. / Depaulo, J Raymond; Simpson, S. G.; Folstein, S.; Folstein, Marshal F.

In: Clinical Chemistry, Vol. 35, No. 7 SUPPL., 1989.

Research output: Contribution to journalArticle

@article{5385d47dbd024d42a90439be24d4fb64,
title = "The new genetics of bipolar affective disorder: Clinical implications",
abstract = "Underrecognition and undertreatment of affective disorders (i.e., major depressive disorder and bipolar affective disorder) constitute a serious public health problem in this country. The recent availability of sufficient mapped restriction fragment length polymorphism (RFLP) probes to cover the human genome and of improved methods of genetic linkage analysis make the definition of the genetic basis of bipolar affective disorders (and recurrent depressions) feasible within the foreseeable future. However, the degree of genetic heterogeneity involved might make the use of tightly linked RFLPs for diagnostic testing, as has been done for Huntington's disease or cystic fibrosis, impractical. Assuming multiple disease loci, then widely applicable and useful 'molecular' diagnostic tests will await the cloning of the disease genes or identification of pathogenic gene products. In addition, the combination of genetic heterogeneity and a substantial degree of assortative mating (i.e., people with affective disorders marrying each other) in families with these disorders could make the search for linked loci a 'bottle-neck' in the path toward developing such diagnostic tests. Recently, three disease loci have been tentatively identified on chromosomes 6, 11, and X.",
author = "Depaulo, {J Raymond} and Simpson, {S. G.} and S. Folstein and Folstein, {Marshal F.}",
year = "1989",
language = "English (US)",
volume = "35",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "7 SUPPL.",

}

TY - JOUR

T1 - The new genetics of bipolar affective disorder

T2 - Clinical implications

AU - Depaulo, J Raymond

AU - Simpson, S. G.

AU - Folstein, S.

AU - Folstein, Marshal F.

PY - 1989

Y1 - 1989

N2 - Underrecognition and undertreatment of affective disorders (i.e., major depressive disorder and bipolar affective disorder) constitute a serious public health problem in this country. The recent availability of sufficient mapped restriction fragment length polymorphism (RFLP) probes to cover the human genome and of improved methods of genetic linkage analysis make the definition of the genetic basis of bipolar affective disorders (and recurrent depressions) feasible within the foreseeable future. However, the degree of genetic heterogeneity involved might make the use of tightly linked RFLPs for diagnostic testing, as has been done for Huntington's disease or cystic fibrosis, impractical. Assuming multiple disease loci, then widely applicable and useful 'molecular' diagnostic tests will await the cloning of the disease genes or identification of pathogenic gene products. In addition, the combination of genetic heterogeneity and a substantial degree of assortative mating (i.e., people with affective disorders marrying each other) in families with these disorders could make the search for linked loci a 'bottle-neck' in the path toward developing such diagnostic tests. Recently, three disease loci have been tentatively identified on chromosomes 6, 11, and X.

AB - Underrecognition and undertreatment of affective disorders (i.e., major depressive disorder and bipolar affective disorder) constitute a serious public health problem in this country. The recent availability of sufficient mapped restriction fragment length polymorphism (RFLP) probes to cover the human genome and of improved methods of genetic linkage analysis make the definition of the genetic basis of bipolar affective disorders (and recurrent depressions) feasible within the foreseeable future. However, the degree of genetic heterogeneity involved might make the use of tightly linked RFLPs for diagnostic testing, as has been done for Huntington's disease or cystic fibrosis, impractical. Assuming multiple disease loci, then widely applicable and useful 'molecular' diagnostic tests will await the cloning of the disease genes or identification of pathogenic gene products. In addition, the combination of genetic heterogeneity and a substantial degree of assortative mating (i.e., people with affective disorders marrying each other) in families with these disorders could make the search for linked loci a 'bottle-neck' in the path toward developing such diagnostic tests. Recently, three disease loci have been tentatively identified on chromosomes 6, 11, and X.

UR - http://www.scopus.com/inward/record.url?scp=0024338918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024338918&partnerID=8YFLogxK

M3 - Article

VL - 35

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 7 SUPPL.

ER -